Newsroom

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Rayonier Advanced Materials Inc. (NYSE: RYAM) today announced the completion of the grant of the employment enducement award to Daniel M. Krawczyk, President and Chief Executive Officer, as previously disclosed in the Company's current report on Form 8-K filed with the Securities and Exchange Commission (the "Commission") on June 22, 2026. Mr. Krawczyk was awarded 202,184 leveraged performance units (“LPUs”), at target, effective June 23, 2026, with the actu...

SASKATOON, Saskatchewan--(BUSINESS WIRE)--Cameco (TSX: CCO; NYSE: CCJ) released its 2025 Sustainability Report today, which communicates the initiatives and key metrics that demonstrate Cameco’s progress to date and the continual advancement of our sustainability reporting. “As I reflect on the past year, I see our commitment to operating sustainably and with integrity embedded in everything we do. It’s evident in how we manage our environmental impacts, in the way we treat our people, and in h...

CHICAGO--(BUSINESS WIRE)--Redemption of Senior Unsecured Notes...

DULUTH, Ga.--(BUSINESS WIRE)--Boxlight Corporation (Nasdaq: BOXL), a leading provider of integrated interactive technology solutions for education, will showcase its unified K–12 technology ecosystem at ISTE 2026 in Orlando, Florida. Anchored by Boxlight Symphony Cloud, Symphony Campus, and the new Symphonic Series, the platform brings together campus communication, school safety, emergency notification, interactive displays, classroom audio, digital signage, and instructional software in one i...

TORONTO--(BUSINESS WIRE)--Sherritt International Corporation (“Sherritt” or the “Corporation”) (TSX:S) today announced that it has filed its unaudited interim financial statements, management’s discussion and analysis and related officer certifications for the three months ended March 31, 2026 (collectively, the “Q1 2026 Filings”). The Q1 2026 Filings are available on SEDAR+ at www.sedarplus.ca. As previously disclosed, the Ontario Securities Commission (the “OSC”), as principal regulator, issu...

BOGOTÁ, Colombia--(BUSINESS WIRE)--rentandes has announced the acquisition of all active renting contracts previously held by Local Colombian Competitor within the country. While the financial terms of the transaction were not disclosed, the deal integrates approximately 1,000 vehicles into the company’s platform. This strategic move continues rentandes’ expansion in the Colombian operating leasing market and ensures seamless service continuity for all newly integrated clients. “This acquisitio...

AHLEN, Alemania--(BUSINESS WIRE)--LR Health & Beauty SE, la empresa líder de Europa en venta directa social de suplementos nutricionales y productos de belleza de calidad superior, ha completado con éxito su reestructuración financiera y de ese modo, sienta las bases para el desarrollo estable y con visión de futuro de la empresa. La consecución de este hito final culmina con éxito un proceso intenso y exigente. LR ha reestructurado de forma fundamental su estructura financiera y ha consoli...

AHLEN, Allemagne--(BUSINESS WIRE)--LR Health & Beauty SE, leader européen du commerce social dans le domaine des compléments alimentaires et des produits de beauté haut de gamme, a mené à bien sa restructuration financière, posant ainsi les bases d’un développement stable et tourné vers l’avenir. Avec le franchissement de cette dernière étape, un processus intense et exigeant a été mené à bien. LR a profondément réorganisé sa structure de financement et considérablement renforcé sa base de...

比利時根特--(BUSINESS WIRE)--(美國商業資訊)-- MRM Health是一家處於臨床階段的生物科技公司，致力於開發以微生物組為基礎的療法以治療免疫介導性疾病。公司今日宣布，隨著企業邁入關鍵成長期，已任命兩位經驗豐富的業界領袖加入董事會。目前，公司先導計畫MH002正處於第2b期臨床開發階段，近期不僅獲得了美國食品藥物管理局(FDA)的快速通道資格，還完成了5500萬歐元的B輪募資。為此，MRM Health正進一步強化董事會陣容，以支援公司達成下一階段的臨床、策略及募資里程碑。Michel Detheux博士已被任命為董事長，接替Werner Cautreels的職務。醫學博士Hans-Jürgen Wörle教授則以獨立董事身分加入董事會。 「MRM Health正步入關鍵發展時期，MH002已推進至第2b期臨床開發階段，公司整體業務動力強勁。對Michel和Hans-Jürgen的任命顯著強化了我們的董事會實力，他們都是藥物開發、監管策略、資本市場、策略交易和購併領域的資深領導者。此次董事會的補強旨在支援MRM Health推進MH002的第2b期臨床試驗，為後...

比利时根特--(BUSINESS WIRE)--(美国商业资讯)-- MRM Health是一家处于临床阶段的生物技术公司，致力于开发基于微生物组的疗法以治疗免疫介导性疾病。公司今日宣布，随着企业迈入关键增长期，已任命两位经验丰富的行业领袖加入董事会。目前，公司先导项目MH002正处于2b期临床开发阶段，近期不仅获得了美国食品药品监督管理局(FDA)的快速通道资格，还完成了5500万欧元的B轮融资。为此，MRM Health正进一步强化董事会阵容，以支持公司达成下一阶段的临床、战略及融资里程碑。Michel Detheux博士已被任命为董事会主席，接替Werner Cautreels的职务。医学博士 Hans-Jürgen Wörle教授则以独立董事身份加入董事会。 “MRM Health正步入关键发展时期，MH002已推进至2b期临床开发阶段，公司整体业务势头强劲。对Michel和Hans-Jürgen的任命显著增强了我们的董事会实力，他们都是药物开发、监管策略、资本市场、战略交易和并购领域的资深领导者。此次董事会的组建旨在支持MRM Health推进MH002的2b期临床试验，为后...